Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade

Background: Neuroendocrine neoplasms (NENs) are a rare group of tumors with a different clinical course, prognosis and location. Radioligand therapy (RLT) can be used as a first or second line of treatment. It is registered in gastroenteropancreatic NENs (GEP-NENs) as grades G1 and G2. Tumors with a...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, Grzegorz Kamiński
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-08-01
Saila:	Pharmaceuticals
Gaiak:	neuroendocrine neoplasms NEN RLT PRRT 177-Lutetium 90-Yttrium
Sarrera elektronikoa:	https://www.mdpi.com/1424-8247/16/9/1205
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!